{
  "id": 15093682,
  "title": "Natera executive chairman Matthew Rabinowitz sells $20.1m in stock",
  "url": "https://urgent.news/2026/10/17/natera-executive-chairman-matthew-rabinowitz-sells-20-1m-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-17T02:01:05.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/natera-executive-chairman-matthew-rabinowitz-sells-201m-in-stock-93CH-4955123"
  },
  "original_language": "en",
  "account": "Matthew Rabinowitz, Executive Chairman of Natera, sold 50,000 shares of the company's stock on October 15, 2026. The sale, worth around $20.1 million, took place pursuant to a pre-authorized trading plan executed on June 12, 2026. The shares were sold at prices ranging from $388.32 to $408.24 per share. Concurrently, Rabinowitz bought 50,000 shares of Natera at $10.41 per share, exercising stock options. Following these transactions, Rabinowitz now owns 2,119,394 shares of Natera stock. Meanwhile, Natera reported second-quarter revenue surpassing expectations at $753 million, leading to an upward revision of its full-year revenue guidance. This strong performance, coupled with Natera's dominant position in the minimal residual disease (MRD) testing market, has attracted attention from financial analysts. Despite a Pro Research Report indicating Natera is overvalued, other firms like RBC Capital and Rothschild Redburn have maintained positive outlooks for the company, highlighting its growth prospects in the healthcare sector.",
  "summary": null,
  "key_points": [
    "Matthew Rabinowitz sold $20.1m worth of Natera stock on October 15, 2026",
    "Rabinowitz exercised stock options to buy 50,000 more shares of Natera",
    "Natera reported Q2 revenue of $753m, raising full-year revenue guidance"
  ],
  "editors_take": "The chairman's pre-planned liquidation of shares amidst strong revenue growth signals a routine rebalancing of personal holdings rather than a lack of confidence in the company's market dominance.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}